Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults with hybrid immunity against COVID-19: a multicenter, partially randomized, platform trial in China DOI Creative Commons
Siyue Jia,

Yihang Liu,

Qian He

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 15, 2024

Abstract Background The primary objective of this research was to assess if a booster dose with COVID-19 vaccines containing ancestral strain could still provide significant protection against symptomatic SARS-CoV-2 infection in predominantly hybrid-immune population during the period omicron variant dominance. Methods We did multicenter, partially randomized, platform trial evaluate effectiveness an aerosolized or intramuscular adenovirus type 5 vectored vaccine (Ad5-nCoV) adults, after national-wide circulating at end year 2022 China. Participants who were willing receive randomly assigned one doses. While, those participants refused take but consented participate surveillance included control group. Both receiving not monitored for six-month period. Results Between May 23, 2023, and August 28, 4089 eligible equally randomized Ad5-nCoV through oral inhalation 0.1mL (IH Ad5-nCoV, n=2039) injection 0.5 mL (IM n=2050). 2008 enrolled blank-control A total 79 cases confirmed, 22 (0.006%) IH group, 23 (0.007%) IM 34 (0.01%) Adjusted from 14 days vaccination 51.6% (95% CI 9.0 74.3) 38.1% - 9.6 65.1), respectively. Interpretation Significant caused by Omicron variant, ongoing pandemic evolving variants, found be provided boosting strain-containing Ad5-nCoV.

Language: Английский

Morris responds to “Critical analyses concerning COVID-19 vaccines need to be consistently critical, and informed” DOI
Jeffrey S. Morris

American Journal of Epidemiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Language: Английский

Citations

0
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China DOI Creative Commons
Siyue Jia, Yuanbao Liu, Qian He

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 26, 2025

We conducted a multicenter, partially randomized, platform trial to assess the effectiveness of booster dose an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in Chinese adults (NCT05855408). Between May 23, 2023, and August 28, 4089 eligible participants were equally randomized receive either Ad5-nCoV via oral inhalation at 0.1 mL (IH Ad5-nCoV, n = 2039) injection 0.5 (IM 2050). Additionally, 2008 who declined but consented participate surveillance enrolled control group. All monitored for symptomatic over six-month period primary outcome. From 14 days after vaccination, (15/1000 person-years), 19 (20/1000 34 (37/1000 person-years) cases confirmed IH group, IM respectively, which resulted adjusted 52.3% (95% CI 10.4 74.6) 37.2% -11.2 64.5) Ad5-nCoV. The was associated with lower incidence COVID-19, there is no solid evidence that more effective than In this clinical trial, authors find orally inhaled during following 6 months compared controls haven't received booster. Intramuscular administered Ad5-CoV reduced as well.

Language: Английский

Citations

0
1 μL, 40min: Multimodal COVID-19 antibody protection evaluation with tip optofluidic immunoassay DOI Creative Commons
Xiaotian Tan, Yujuan Chai, Ruihan Li

et al.

hLife, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV DOI Creative Commons
Zhe Zhang, Xiangyang Chi,

Guan-Ying Zhang

et al.

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 23, 2024

We administered a questionnaire to participants who received different vaccination regimens evaluate the effectiveness of Ad5-vectored COVID-19 vaccines. The results showed that administration intramuscular Ad5-nCoV provided 21.32% more protection against SARS-CoV-2 infection than inactivated vaccine in people had only one type vaccine. Furthermore, aerosolized exhibited good protection, whether it was as homologous booster vaccinated with or heterologous Our research indicates is an effective booster. This finding supports future selection immunization strategies.

Language: Английский

Citations

1
Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults with hybrid immunity against COVID-19: a multicenter, partially randomized, platform trial in China DOI Creative Commons
Siyue Jia,

Yihang Liu,

Qian He

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 15, 2024

Abstract Background The primary objective of this research was to assess if a booster dose with COVID-19 vaccines containing ancestral strain could still provide significant protection against symptomatic SARS-CoV-2 infection in predominantly hybrid-immune population during the period omicron variant dominance. Methods We did multicenter, partially randomized, platform trial evaluate effectiveness an aerosolized or intramuscular adenovirus type 5 vectored vaccine (Ad5-nCoV) adults, after national-wide circulating at end year 2022 China. Participants who were willing receive randomly assigned one doses. While, those participants refused take but consented participate surveillance included control group. Both receiving not monitored for six-month period. Results Between May 23, 2023, and August 28, 4089 eligible equally randomized Ad5-nCoV through oral inhalation 0.1mL (IH Ad5-nCoV, n=2039) injection 0.5 mL (IM n=2050). 2008 enrolled blank-control A total 79 cases confirmed, 22 (0.006%) IH group, 23 (0.007%) IM 34 (0.01%) Adjusted from 14 days vaccination 51.6% (95% CI 9.0 74.3) 38.1% - 9.6 65.1), respectively. Interpretation Significant caused by Omicron variant, ongoing pandemic evolving variants, found be provided boosting strain-containing Ad5-nCoV.

Language: Английский

Citations

0